InSilico Medicine Cayman (3696) Q2 2026 earnings summary

Executive summary

• Achieved first-ever profitability in H1 2026 with net profit of $35.5M (GAAP) and adjusted profit of $51.2M (non-IFRS), reversing a $19.2M loss in H1 2025.

• Revenue surged 287.2% year-over-year to $106.3M, driven by out-licensing, collaborations, and drug discovery pipeline development.

• Gross margin improved to 90.3% from 83.8% year-over-year, reflecting a shift to higher-margin pipeline revenue.

• Maintained strong cash reserves of $585M as of June 30, 2026, supporting multi-year runway and business expansion.

• Signed major pharma and biotech deals totaling $11B in value, with $308M received and $10.6B in future milestones.

Financial highlights

• Revenue increased from $27.5M in H1 2025 to $106.3M in H1 2026 (+287.2%).

• Gross profit margin rose to 90.3% from 83.8% year-over-year.

• Operating expenses grew to $68.3M, reflecting increased R&D investment.

• Cash from operating activities reached $79M, turning cash positive.

• Adjusted profit (non-IFRS) was $51.2M, versus adjusted loss of $15.4M in H1 2025.

Outlook and guidance

• Expect continued pipeline expansion with more PCC nominations in obesity, anti-inflammation, and autoimmune diseases.

• Anticipate new strategic collaborations and AI platform launches, including generative AI and significant scientific publications.

• Phase III trial for IPF (Rentosertib/ISM001-055) to enroll first patient in H2 2026; multiple clinical milestones expected.